Mechanism of Sedative Action and the Role of the BBB
For a drug to influence the regulation of sleep and wakefulness, it must reach the brain tissues. The human body has several isolating barriers (such as the blood-testisticular, blood-ocular, and placental barriers), but the blood-brain barrier (BBB) plays the key role in neuropharmacology.
H1-histamine receptor blockers used as hypnotics have a high capacity to cross the blood-brain barrier. Once in the central nervous system tissues, the active substances specifically block H1 receptors. This pharmacodynamic interaction leads to a general central nervous system depression, which clinically manifests as a pronounced sedative and hypnotic effect.
Diphenhydramine: From Antiallergic to Sedative
One of the most well-known classical representatives of this group is diphenhydramine.
Historically and pharmacologically, diphenhydramine is classified as an antiallergic agent. However, its ability to penetrate the central nervous system causes a strong nervous system depression. In clinical practice, this pronounced hypnotic effect was initially considered purely a side effect. Nevertheless, due to its potency and predictability, this side effect of diphenhydramine has come to be purposefully utilized for therapeutic management of sleep disorders.
Doxylamine: A Specialized Hypnotic Agent
Unlike drugs where central nervous system depression is merely a secondary effect, H1-histamine receptor blockers also include agents developed specifically for the treatment of insomnia. A prominent example of this targeted approach is doxylamine.
Key advantages of doxylamine:
- Preservation of sleep architecture: The drug does not disrupt the delicate physiological structure of sleep, allowing the body to properly transition through all necessary normal rest phases.
- Safety profile: Compared to a number of other central nervous system depressants, doxylamine is characterized by objectively low toxicity, making its use safer for patients.